Logo of Phnom Penh Post newspaper Phnom Penh Post - J&J booster trims severe Omicron cases, study finds



J&J booster trims severe Omicron cases, study finds

Content image - Phnom Penh Post
The Johnson & Johnson (J&J) Covid vaccine. AFP

J&J booster trims severe Omicron cases, study finds

A preliminary South African government study published on December 30 showed a booster of the Johnson & Johnson (J&J) Covid vaccine was 85 per cent effective in preventing hospitalisation from the Omicron variant, a finding that helps revive the shot’s reputation.

The South African Medical Research Council compared 69,000 health care workers who received two doses of the vaccine, based on viral vector technology, against a group of people who were unvaccinated.

The research, which has not yet been peer reviewed, was conducted from November 15 to December 20, a time when the heavily-mutated Omicron variant increased from 82 to 98 per cent of Covid-19 cases in the country.

When a booster shot was given six to nine months after the first dose, vaccine efficacy against hospitalisation increased over time, from 63 per cent at 0-13 days to 85 per cent one to two months post-boost.

“This data is important given the increased reliance on the Ad26.COV.2 vaccine in Africa,” wrote the authors, using the formal name for the J&J shot.

The result was also hailed by the company. In a statement, J&J scientist Mathai Mammen said it showed the vaccine “remains strong and stable over time, including against circulating variants such as Omicron and Delta”.

Around half a million South African health staff have received Johnson jabs as part of clinical trials.

Africa’s hardest-hit country, South Africa has recorded more than 3.4 million cases and 90,000 deaths since the start of the pandemic.

An earlier South African study in December found that two doses of the Pfizer-BioNTech vaccine prevented hospital admissions by up to 70 per cent. Results for three doses of that vaccine aren’t yet known.

The news comes weeks after the US formally recommended mRNA vaccines, made by Pfizer and Moderna, over the J&J shot, because of greater risks related to a rare form of blood clotting.

Preliminary lab studies had also shown that the J&J vaccine triggers fewer neutralising antibodies – Y-shaped proteins that block infection – against the heavily mutated Omicron variant, compared to mRNA vaccines, and it was suggested that it would be less effective in real life too.

The reason it performs better in the real world than some expected could be it evokes a heightened response of another part of the immune system, known as cellular immunity.

A separate, small analysis carried out by the Beth Israel Deaconess Medical Center in the northeastern US city of Boston on 65 individuals found that a J&J booster on top of two doses of the Pfizer Covid vaccine might provide greater protection than three doses of the Pfizer vaccine.

Though antibody levels surged to high levels after three doses of Pfizer, they also waned within a few weeks, while they rose steadily after two Pfizer shots and a J&J shot, and were at higher levels after four weeks.

Boosting with the J&J vaccine also elicited a strong increase in “killer T cells”.

Though they can’t stop infection, killer T cells search for cells that have been infected with the virus and destroy them, helping prevent severe illness. They are able to withstand variants far better than antibodies.

Overall, the data might mean that mix-and-match boosting could provide stronger protection than continuing with the same vaccine, but the long-term durability of both strategies needs further study, said J&J.

MOST VIEWED

  • Hong Kong firm done buying Coke Cambodia

    Swire Coca-Cola Ltd, a wholly-owned subsidiary of Hong Kong-listed Swire Pacific Ltd, on November 25 announced that it had completed the acquisition of The Coca-Cola Co’s bottling business in Cambodia, as part of its ambitions to expand into the Southeast Asian market. Swire Coca-Cola affirmed

  • Moody’s sets outlook rating to ‘negative’ for Cambodia

    US global rating agency Moody’s Investors Service Inc on November 15 announced that it downgraded Cambodia’s outlook from “stable” to “negative” and maintained its B2 local and foreign currency issuer ratings. “The negative outlook reflects a deteriorating external position as illustrated by the severe

  • NagaWorld union leader arrested at airport after Australia trip

    Chhim Sithar, head of the Labour Rights Supported Union of Khmer Employees at NagaWorld integrated casino resort, was arrested on November 26 at Phnom Penh International Airport and placed in pre-trial detention after returning from a 12-day trip to Australia. Phnom Penh Municipal Court Investigating Judge

  • Korean first lady paves way for ill boy’s surgery

    A 14-year-old boy with congenital heart disease who was lucky enough to meet with South Korean first lady Kim Keon-hee may get the chance of a lifetime and receive surgery and treatment at Asan Medical Center in Seoul, South Korea. After seeing his plight, many

  • Hun Sen’s Covid infection caused by ‘weakened antibody’ after summit

    Prime Minister Hun Sen said exhaustion from heavy workload before and during the recent ASEAN Summit may have led to him contracting Covid-19 due to his weakened immune system, while rejecting speculations that the infection was caused by leaders of some countries who did not

  • Kingdom’s rice crowned world’s No1

    Cambodia’s Phka Rumduol jasmine variety has been crowned the World’s Best Rice for the fifth time at the TRT (The Rice Trader) World Rice Conference in Phuket, Thailand on November 17, according to leaders of the Kingdom’s apex rice industry body. Phka Rumduol